Literature DB >> 16820216

The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis.

Mathula Thangarajh1, Thomas Masterman, Lars Helgeland, Uros Rot, Malin V Jonsson, Geir Egil Eide, Ritva Pirskanen, Jan Hillert, Roland Jonsson.   

Abstract

The accumulation of B cells in the thymus is a common feature of myasthenia gravis (MG). To understand whether factors enhancing B-cell survival are increased in MG, we studied the expression of APRIL, BAFF and three of their receptors in the thymus. In hyperplastic thymi, macrophages expressed APRIL and BAFF, and germinal-center B cells, BAFF-R. CD138-positive plasma cells were abundant in MG thymi. By contrast, BCMA-positive plasma cells were scarce. The expression of APRIL and BAFF in MG thymi may reflect the establishment of an environment favorable to B-cell survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820216     DOI: 10.1016/j.jneuroim.2006.05.023

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  BAFF serum levels in myasthenia gravis: effects of therapy.

Authors:  Flavia Scuderi; Paolo E Alboini; Emanuela Bartoccioni; Amelia Evoli
Journal:  J Neurol       Date:  2011-05-11       Impact factor: 4.849

Review 2.  Regulatory roles of the tumor necrosis factor receptor BCMA.

Authors:  Christine M Coquery; Loren D Erickson
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

Review 3.  Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.

Authors:  Fiammetta Vanoli; Renato Mantegazza
Journal:  Neurotherapeutics       Date:  2022-02-14       Impact factor: 6.088

4.  B-cell-activating factor and autoimmune myasthenia gravis.

Authors:  Samia Ragheb; Robert P Lisak
Journal:  Autoimmune Dis       Date:  2011-11-28

5.  Changes in inflammatory cytokine networks in myasthenia gravis.

Authors:  Akiyuki Uzawa; Tetsuya Kanai; Naoki Kawaguchi; Fumiko Oda; Keiichi Himuro; Satoshi Kuwabara
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

6.  Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?

Authors:  Paola Cavalcante; Stefania Marcuzzo; Sara Franzi; Barbara Galbardi; Lorenzo Maggi; Teresio Motta; Raffaella Ghislandi; Antonella Buzzi; Luisella Spinelli; Lorenzo Novellino; Fulvio Baggi; Carlo Antozzi; Fabio Conforti; Tommaso Martino De Pas; Massimo Barberis; Pia Bernasconi; Renato Mantegazza
Journal:  Oncotarget       Date:  2017-09-08

7.  Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms.

Authors:  Annie George-Chandy; Estelle Trysberg; Kristina Eriksson
Journal:  Arthritis Res Ther       Date:  2008-08-22       Impact factor: 5.156

8.  Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study.

Authors:  Linda L Kusner; Michael J Ciesielski; Alexander Marx; Henry J Kaminski; Robert A Fenstermaker
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

Review 9.  BAFF and BAFF-Receptor in B Cell Selection and Survival.

Authors:  Cristian R Smulski; Hermann Eibel
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

10.  Lower BAFF Levels in Myasthenic Patients Treated with Glucocorticoids.

Authors:  Ewa Sobieszczuk; Piotr Szczudlik; Justyna Kubiszewska; Beata Szyluk; Marta Lipowska; Małgorzata Dutkiewicz; Anna Kostera-Pruszczyk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-08-02       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.